The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
The ever-increasing burden of type 2 diabetes mellitus (T2DM) worldwide, has led to the emergence of several antidiabetes drugs with different modes of action. Incretin hormones and their effect on glucose metabolism and pathogenesis of T2DM has been a landmark discovery in the management of this in...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3f80af6f0ce043bc92ebdb42b6a1472a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:3f80af6f0ce043bc92ebdb42b6a1472a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:3f80af6f0ce043bc92ebdb42b6a1472a2021-11-14T09:00:22ZThe role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future2072-03512072-037810.14341/DM11493https://doaj.org/article/3f80af6f0ce043bc92ebdb42b6a1472a2019-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/11493https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The ever-increasing burden of type 2 diabetes mellitus (T2DM) worldwide, has led to the emergence of several antidiabetes drugs with different modes of action. Incretin hormones and their effect on glucose metabolism and pathogenesis of T2DM has been a landmark discovery in the management of this increasingly prevalent metabolic disorder. Glucagon like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are the two major classes of incretin-based therapies that regulate glucose mechanism through multiple pathways, demonstrate weight loss (GLP-1 receptor agonists) or a weight-neutral effect (DPP-4 inhibitors), and are associated with a low risk of hypoglycaemia and other adverse events. In addition, evidence reflects their possible therapeutic potential in the treatment of other clinical conditions such as obesity, cardiovascular disease and liver disorders. This review explores the availability and the impact of GLP-1 receptor agonists and DPP-4 inhibitors as potential therapeutic strategies for T2DM along with their future in the landscape of diabetes management and other clinical conditions.Juris J. MeierEndocrinology Research Centrearticlecardiovasculardipeptidyl peptidase-4 inhibitorsglucose-dependent insulinotropic polypeptideglucagon like peptide -1glp-1 receptor agonistsincretin-based therapiestype 2 diabetes mellitusNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 5, Pp 461-466 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
cardiovascular dipeptidyl peptidase-4 inhibitors glucose-dependent insulinotropic polypeptide glucagon like peptide -1 glp-1 receptor agonists incretin-based therapies type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
cardiovascular dipeptidyl peptidase-4 inhibitors glucose-dependent insulinotropic polypeptide glucagon like peptide -1 glp-1 receptor agonists incretin-based therapies type 2 diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627 Juris J. Meier The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future |
| description |
The ever-increasing burden of type 2 diabetes mellitus (T2DM) worldwide, has led to the emergence of several antidiabetes drugs with different modes of action. Incretin hormones and their effect on glucose metabolism and pathogenesis of T2DM has been a landmark discovery in the management of this increasingly prevalent metabolic disorder. Glucagon like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are the two major classes of incretin-based therapies that regulate glucose mechanism through multiple pathways, demonstrate weight loss (GLP-1 receptor agonists) or a weight-neutral effect (DPP-4 inhibitors), and are associated with a low risk of hypoglycaemia and other adverse events. In addition, evidence reflects their possible therapeutic potential in the treatment of other clinical conditions such as obesity, cardiovascular disease and liver disorders. This review explores the availability and the impact of GLP-1 receptor agonists and DPP-4 inhibitors as potential therapeutic strategies for T2DM along with their future in the landscape of diabetes management and other clinical conditions. |
| format |
article |
| author |
Juris J. Meier |
| author_facet |
Juris J. Meier |
| author_sort |
Juris J. Meier |
| title |
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future |
| title_short |
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future |
| title_full |
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future |
| title_fullStr |
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future |
| title_full_unstemmed |
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future |
| title_sort |
role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future |
| publisher |
Endocrinology Research Centre |
| publishDate |
2019 |
| url |
https://doaj.org/article/3f80af6f0ce043bc92ebdb42b6a1472a |
| work_keys_str_mv |
AT jurisjmeier theroleofincretinbasedtherapiesinthemanagementoftype2diabetesmellitusperspectivesonthepastpresentandfuture AT jurisjmeier roleofincretinbasedtherapiesinthemanagementoftype2diabetesmellitusperspectivesonthepastpresentandfuture |
| _version_ |
1718429519948283904 |